文献速递其他结缔组织病

系统性硬化症试验设计的挑战

Challenges in systemic sclerosis trial design.
PubMed 文献 · Semin Arthritis Rheum · 2019-01-01

系统性硬化症(SSc)是病死率最高的风湿病,约半数患者最终直接死于SSc,目前尚无获批的疾病修饰治疗。传统终点MRSS在安慰剂组也常改善,新开发的复合应答指数CRISS获ACR临时认可,但单独使用难以说服监管机构,需结合反映患者感受、功能或生存的领域变化。

要点

  • SSc缺乏获批的疾病修饰治疗,试验设计困难是重要原因之一。
  • MRSS与生存和并发症风险相关,但在安慰剂组也常随时间改善,存在局限。
  • CRISS复合指标获ACR临时认可,但单独使用说服监管机构力度不足。

核心结论

  • SSc临床试验面临终点选择困难,MRSS存在安慰剂组也改善的局限,CRISS虽有前景但单独使用不足以说服监管机构。

研究设计与样本

  • 原文为Semin Arthritis Rheum发表的关于系统性硬化症试验设计挑战的论述,未报告具体研究设计与样本量。

主要发现

  • SSc是病死率最高的风湿病,约半数患者最终直接死于SSc,目前无获批的疾病修饰治疗。
  • MRSS与生存和并发症风险相关,但近期试验显示其在安慰剂组也常随时间改善。
  • CRISS整合肺功能、皮肤、患者与医师整体评估及HAQ残疾指数等多个领域的变化,获ACR临时认可。

关键数值与推荐

  • CRISS获美国风湿病学会临时认可( designated ACR CRISS),但单独使用难以强烈说服监管机构,除非相关领域同时有反映患者感受、功能或生存的临床有意义变化。

临床怎么用

  • 在SSc试验设计中应关注MRSS的安慰剂效应局限,并考虑采用CRISS等复合指标,同时确保相关领域有反映患者感受、功能或生存的临床有意义变化。

局限性

  • 原文未报告具体研究设计、样本量或统计数值,相关局限信息未涉及。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Systemic sclerosis (scleroderma; SSc) is an autoimmune rheumatic disease with high clinical burden and unmet need due to connective tissue fibrosis and vascular damage. It has the highest case specific mortality of any rheumatic disease, with approximately half of patients diagnosed eventually dying as a direct result of SSc. There are no approved diseases modifying treatments. This is partly related to the difficulty of conducting clinical trials for regulatory approval. Traditionally skin thickness has been assessed using the modified Rodnan skin score (MRSS) that has been shown to correlate with survival and risk of complications in SSc. However recent trials have highlighted the limitations of MRSS which often improves over time, even on placebo. A new composite measure integrating changes in multiple domains of lung function, skin, patients and physician global and HAQ disability index has been developed, the CRISS (Composite Response Index for Systemic Sclerosis). This measure looks promising and has provisional acceptance by American College of Rheumatology (designated ACR CRISS) but is unlikely to be strongly persuasive to Health Authorities in isolation unless there are also clinically meaningful changes in relevant domains that reflect how patients feel, function or survive.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Denton CP. Challenges in systemic sclerosis trial design. Semin Arthritis Rheum. 2019. PMID: 31779848. doi:10.1016/j.semarthrit.2019.09.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。